Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96

Trial Profile

Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2015

At a glance

  • Drugs HSP Gp96 vaccine Cure and Sure Biotech (Primary) ; Gimeracil/oteracil/tegafur; Oxaliplatin
  • Indications Gastric cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top